Drugs / CMV/HIV-CAR T Cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06252402 | Dec 2024 → Dec 2026 expected | — | City of Hope Medical Center | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CMV/HIV-CAR T Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06252402 ↗ |
| Action | Deplete | “may provide a safe and effective way to eliminate HIV-infected cells” NCT06252402 ↗ |
| Modality | Cell therapy | “autologous bispecific CMV/HIV-CAR T cells” NCT06252402 ↗ |
| Route | Intravenous | “single intravenous (IV) infusion of autologous CMV/HIV-CAR T cells” NCT06252402 ↗ |